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Background:  To  evaluate  the potential  public  health  impact  of the  live  attenuated  tetravalent  Sanoﬁ  Pas-
teur dengue  vaccine  (CYD-TDV)  we  analyzed  data  from  the  reported  clinical  trials  to calculate  vaccine
preventable  disease  incidence  (VPDI)  and  number  needed  to  vaccinate  (NNV)  based  on the  licensure
indication  for  persons  age  9 years  and  above.
Methods:  VPDI  is  deﬁned  as  incidence  in an  unvaccinated  population  X  vaccine  efﬁcacy  (VE),  and  thus
incorporates  both  VE  and  the  underlying  burden  of  disease.  NNV  was  calculated  as  100,000  divided  by
VPDI  divided  by 2-year  length  of  study.  We  compared  these  values  to data  for three  newer  vaccines  that
are  currently  integrated  into  some  national  immunization  programs  in  Asia  and  Latin  America,  namely
pneumococcal  conjugate,  Haemophilus  inﬂuenzae  type  b, and  rotavirus  vaccines.
Results:  In  the  Asian-Paciﬁc  trial,  in the  ﬁrst  25  months  after  the  ﬁrst  dose  of  the  dengue  vaccine,  CYD-TDV
prevented  annually  2639  cases  of virologically  conﬁrmed  dengue  for every  100,000  persons  vaccinated,
for an  NNV  of  18. In the  Latin  American  trial,  given  the  overall  lower  annual  dengue  incidence  compared
to  Asia,  VPDI  was 1707, and NNV  28.  For  the  Asian-Paciﬁc  and  Latin  American  studies,  the  VPDIs  for
hospitalized  virologically  conﬁrmed  disease  at the  trials’  end  were  638  and  239 per 100,000  population
per  year,  respectively,  with  NNVs  of 75  and  201.  VPDI  for conﬁrmed  dengue  hospitalization  was  higher
than  that  for Hib  vaccine  against  Hib  meningitis  or all cause  severe  pneumonia  while  lower  than  that  for
rotavirus  vaccine  against  severe  rotavirus  gastroenteritis.
Conclusions:  Our  analysis  found  that  the CYD-TDV  dengue  vaccine  had  favorable  VPDI  and  NNV,  also
when  compared  to existing  vaccines  used  in Latin  America  and  Asia.  VPDI  and  NNV  varied  by serotype
distribution,  extent  of prior  dengue  exposure  (baseline  seroprevalence)  and country.  These  ﬁndings  will
help policy-makers  decide  where  and  how  to introduce  this  vaccine  post-licensure.
©  2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Dengue is an arboviral disease that poses a signiﬁcant public
ealth burden in most countries in the tropics and subtropics. With
ome 100 million cases estimated to occur annually, many of which
ead to hospitalizations, dengue outbreaks can overwhelm already
Abbreviations: Hib, Haemophilus inﬂuenzae type b; NNV, number needed to vac-
inate; RCT, randomized clinical trial; VE, vaccine efﬁcacy; VPDI, vaccine preventable
isease incidence.
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fragile health care systems [1]. The often unpredictable nature of
dengue outbreaks further aggravates the public health impact. The
increasing incidence and geographic expansion of dengue trans-
mission in the past two  decades, accompanied by the increasing
socioeconomic burden compounded by costly yet still ineffective
vector control strategies, underpin the urgent need for a dengue
vaccine [2].
The live attenuated recombinant tetravalent Sanoﬁ Pasteur
dengue vaccine CYD-TDV was  assessed during a 25-month efﬁ-
cacy surveillance phase (Phase 3 trial). Conducted in ten endemic
countries in Asia and Latin America, two  multi-center efﬁcacy tri-
als involved more than 31,000 subjects with an age range from 2
to 16 years [3,4]. The overall efﬁcacy for all age groups in both tri-
als was 54% for virologically conﬁrmed dengue of any severity or
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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erotype [5]. The efﬁcacy against virologically conﬁrmed dengue
f any severity and serotype, hospitalizations, and severe disease
as consistently higher in those aged 9–16 years than younger sub-
ects [5]. Because of the lower efﬁcacy and the transient reversed
isk:beneﬁt observed in the third year in younger children [5] the
ge group anticipated to beneﬁt most from this vaccine, and the
ge group for which the manufacturer is seeking licensure, is indi-
iduals from the age of 9 years and above [6]. In this age group, the
verall efﬁcacy in the ﬁrst 25 months (13 months after the third
ose) against virologically conﬁrmed dengue was 65%, against hos-
italization 81% and against severe disease 93% [5]. Follow-up is
till ongoing to assess long-term efﬁcacy and safety. Meanwhile,
he vaccine has been licensed in at least 4 countries for the age
ange of 9–45 years.
Efﬁcacy results obtained from randomized controlled trials
RCTs) are important for licensure. In an RCT, efﬁcacy provides
 measure of proportionate reduction at individual level. How-
ver, evidence-informed introduction of vaccines into national
rograms, once a dengue vaccine is indeed licensed, cannot only
e driven by efﬁcacy because efﬁcacy indicates whether a vaccine
orks against a speciﬁc outcome rather than providing information
n the vaccine’s public health impact. In addition to the prevention
f infection at individual level, the ultimate goal of vaccination is
o decrease the public health burden of disease at the population
evel. Hence, an additional measure to efﬁcacy that more directly
stablishes a vaccine’s public health importance is the vaccine pre-
entable disease incidence (VPDI) [7]. VPDI is the incidence of given
isease syndrome preventable by vaccine in a given context [7].
urthermore, the number needed to vaccine (NNV) is often used
s a metric of the value of vaccination programs, and can also be
sed for cost effectiveness studies. NNV is a measure to quantify
he number of people, or the number of vaccine doses, needed to
revent one event due to disease and allow the calculation [8].
To evaluate the potential public health impact of the CYD-TDV
engue vaccine beyond the efﬁcacy data already published, we
able 1
alculation of dengue vaccine preventable disease incidence (VPDI) and number needed
or  virologically conﬁrmed dengue cases, calculated from data abstracted from Figures 2 
Outcome Region Intervention
cases
Control
cases
Interven
incidenc
Hospitalized dengue
All hospitalized Both regions 27 70 75 
Asian-Paciﬁc 10 27 151 
Latin America 17 43 61 
Severe
hospitalized
Both  regions 3 22 8 
Asian-Paciﬁc 2 11 29 
Latin America 1 11 3 
All  dengue cases
All serotypes Both regions 367 521 1022 
Asian-Paciﬁc 90 136 1357 
Latin America 277 385 995 
Serotype 1 Asian-Paciﬁc 36 52 543 
Latin America 99 109 356 
Serotype 2 Asian-Paciﬁc 33 26 498 
Latin America 84 84 302 
Serotype 3 Asian-Paciﬁc 11 18 166 
Latin America 55 106 198 
Serotype 4 Asian-Paciﬁc 10 41 151 
Latin America 32 83 115 
Baseline
seropos.b
Asian-Paciﬁc 7 17 690 
Latin America 8 23 358 
Baseline
seroneg.b
Asian-Paciﬁc 7 8 2605 
Latin  America 9 9 1674 
a Annual incidence per 100,000 persons.
b Baseline seropositivity was  determined for only a subset of enrolled subjects; consequ
enominators for the Asian-Paciﬁc region were 3316 and 1656 for vaccinated and contr
940.  For baseline seropositive, denominators for the Asian-Paciﬁc region were 487 and
aseline  seronegative, denominators for the Asian-Paciﬁc region were 129 and 59 for vacccine 34 (2016) 2397–2401
analyzed data from the previously reported clinical trials [3–5] to
calculate VPDI and NNV based on the target indication of ages 9
years and above. To provide context to these ﬁndings, for Latin
America we  compare these values to data for three vaccines with
clinical trial data from Latin America and that are currently inte-
grated into most national immunization programs in the region,
namely pneumococcal conjugate [9], Haemophilus inﬂuenzae type
b [10], and rotavirus vaccines [11].
2. Methods
Measurement of VPDI is deﬁned as: incidence in an unvacci-
nated population X vaccine efﬁcacy (VE), and thus incorporates
both VE and the underlying burden of disease [12]. This is math-
ematically equivalent to the incidence in the control group minus
the incidence in the intervention group. In principle VPDI is best
calculated from community randomized trials as this allows incor-
poration of the vaccine’s ability to prevent disease through both
direct and indirect mechanisms. Additionally, it is best calculated
for clinically rather than etiologically deﬁned endpoints as this
adjusts for the inevitable failure to conﬁrm all prevented outcomes.
However, currently published data [3–5] are limited to the individ-
ually randomized trials that report VE against etiologically deﬁned
outcomes, which will provide a lower bound of true VPDI.
While incidence densities for all virologically conﬁrmed dengue
were presented in the separate regional reports [3,4], these reports
did not present data that would allow incidence calculations for
severe or hospitalized dengue and the Asian manuscript did not
present data separately for the 9–16 year old age group. Conse-
quently, we used the pooled analysis [5] for the current study,
based on intention-to-treat analysis, as this presented data on
all and hospitalized virologically conﬁrmed dengue stratiﬁed by
age group. For children age 9–16 years, data for all dengue were
obtained from Figure 2 and for hospitalized dengue from Figure
3 [5]. Because summary years of follow-up were not reported,
 to vaccinate (NNV) (with conﬁdence intervals) based on two-year follow-up data
and 3 of Ref. [5].
tion
ea
Control
incidencea
Vaccine
efﬁcacy
VPDI* (95% CI)a NNV (95% CI)
391 81% 316 (226, 422) 152 (114, 213)
815 82% 638 (365, 1008) 75 (48, 132)
310 80% 239 (154, 346) 201 (139, 313)
123 93% 114 (72, 178) 419 (270, 667)
319 91% 290 (130, 528) 166 (91, 370)
76 96% 73 (34, 134) 661 (357, 1429)
2909 66% 1887 (1632, 2160) 25 (22, 29)
4106 68% 2639 (1968, 3360) 18 (14, 24)
2774 65% 1707 (1440, 2016) 28 (24, 33)
1570 66% 986 (576, 1488) 49 (32, 83)
785 55% 412 (264, 576) 116 (83, 182)
785 37% 276 (0, 672) 174 (71, undeﬁned)
605 50% 291 (158, 437) 165 (110, 303)
543 70% 363 (134, 672) 132 (71, 357)
764 74% 543 (403, 720) 88 (67, 119)
1238 88% 1044 (720, 1488) 46 (32, 67)
598 81% 464 (346, 624) 104 (77, 139)
3251 79% 2561 (1162, 4416) 19 (11, 41)
2156 84% 1798 (1008, 2832) 27 (17, 48)
6508 62% 3904 (−149, 9360) 12 (5, undeﬁned)
2899 43% 1225 (−768, 3768) 39 (13, undeﬁned)
ently, the denominator for these outcomes is different than for all other outcomes.
ol subjects, respectively, for all enrolled subjects and for Latin America 13,914 and
 251 for vaccinated and control subjects and for Latine America 1073 and 512. For
cinated and control subjects and for Latin America 258 and 149.
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Table  2
Calculation of dengue vaccine preventable disease incidence (VPDI) and number
needed to vaccinate (NNV) per country, in Latin Americaa based on 25 months
follow-up data for virologically conﬁrmed dengue cases.
Country Control incidence
density
Vaccine efﬁcacy (VE) VPDIb NNV
Brazil 3.7 77.5% 2.9 17
Colombia 2.7 67.5% 1.8 27
Honduras 4.0 71.1% 2.8 18
Mexico 2.5 31.3% 0.8 64
Puerto Rico 1.6 57.6% 0.9 54
a The only published data stratiﬁed by country for the Asian-Paciﬁc region are
in  Appendix Table 1 [3] and these include all age groups down to age 2 years.
Consequently, we  do not present country-stratiﬁed data for this region.
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ence density multipled by vaccine efﬁcacy. Raw data were not presented, so
onﬁdence limits were not calculated.
e estimated incidence as cases divided by number of subjects
nrolled divided by length of the study, in this case 25 months or
.1 years, times 100,000 to provide cases prevented per 100,000
ersons per year. Unlike VPDI, NNV is not a rate but instead the
verall number of cases prevented for a given number of persons
accinated, and thus incorporates the length of the trial. NNV was
alculated as (100,000 divided by VPDI divided by 2.1-year length
f study).
To calculate the 95% conﬁdence intervals for VPDI in Table 1, we
sed Vassarstats (website: http://vassarstats.net/prop2 ind.html,
ast accessed February 28, 2016) as in this case VPDI was calcu-
ated as the difference between annual incidences. For Table 2, we
sed OpenEpi (website: http://www.openepi.com/PersonTime2/
ersonTime2.htm, last accessed February 28, 2016) to calculate the
PDI 95% conﬁdence intervals since in this case incidence densities
ere available.
Decision-makers do not judge a vaccine’s importance in a
acuum but rather against other options for public health inter-
entions. To provide context, for Latin America we compared the
alculation of VPDI and NNV for dengue vaccine to that for pneu-
ococcal conjugate [9], Hib [10], and rotavirus [11] vaccines. For
sia, we used comparison data for Hib [13] and rotavirus [14] vac-
ines. These vaccines were selected for two reasons: (1) clinical
rials existed speciﬁcally from Latin America or Asia that allowed
alculation of VPDI and in all cases but the Asian Hib vaccine study
or NNV; (2) some or most countries in the respective region have
able 3
omparison of vaccine preventable disease incidence (VPDI) and number needed to vaccin
nto  national immunization programs in Latin America. VPDI reported as cases per 100,00
Etiology Outcome 
Dengue [5] a All virologically conﬁrmed clinical cas
All virologically conﬁrmed hospitalize
All virologically conﬁrmed severe hos
cases
Rotavirus [11]b Conﬁrmed rotavirus hospitalization 
All cause gastroenteritis hospitalizatio
All cause severe gastroenteritis hospit
Pneumococcus
[9] c
Vaccine serotype invasive pneumococ
Consolidated community acquired pn
(CAP)
CAP with radiographic conﬁrmation o
consolidation or pleural effusion
Clinically suspected CAP 
Haemophilus inﬂuenzae type b (Hib) [10] d All pneumonia hospitalizations with c
effusion, bronchial breath sounds, or e
erythrocyte sedimentation rate
a Data calculated for persons 9 to 16 years of age and 2 year follow-up period.
b Data from 10 Latin American countries plus Finland, for infants followed from infant 
c Data from three Latin American countries, for children followed from infant immuniza
f  observation (PYO).
d Data from Chile, for children followed infant immunization to age 2 years. VPDI reporccine 34 (2016) 2397–2401 2399
included these vaccines in their national immunization programs
and thus have already concluded that they represent efﬁcient
use of resources. A speciﬁc subtlety was that some studies used
person-years of observation and others used persons vaccinated to
calculate incidences in study groups, and this is noted in the data we
present. Calculation of NNV in all cases was done only if the number
of persons vaccinated by intervention and control populations was
available.
3. Results
For the primary endpoint of all virologically conﬁrmed dengue
cases in subjects aged 9 years and above, based on VE data reported
at the 2.1 year follow-up, the Asian Paciﬁc study reported control
and intervention group annual incidences of 3942 and 1303 per
100,000 vaccinated subjects, respectively, which translates into an
annual VPDI of 2639 per 100,000 (Table 1). Phrased differently,
the CYD-TDV dengue vaccine prevented 2639 cases of virologically
conﬁrmed dengue yearly for every 100,000 persons vaccinated, for
an NNV over the 2.1 year study period of 18. Similar results for
control and intervention group incidences and VPDI in the Latin
American study were 2663, 956, and 1707 per 100,000 population;
the NNV was 28. For the Asian-Paciﬁc and Latin American regions,
the annual VPDIs for hospitalized virologically conﬁrmed disease
at the end of two years were 638 and 239 per 100,000 population,
respectively, with NNVs of 75 and 201, with lower VPDIs and higher
NNVs for severe hospitalized dengue.
Serotype 4 had the most favorable VPDI and NNV, followed by
serotype 1 (Table 1). Among the subgroup with baseline seropreva-
lence determined, VE was lower in both Asia and Latin America for
those who  were seronegative. Despite this, in Asia VPDI was higher
and NNV lower for persons seronegative at baseline while the oppo-
site was  true in Latin America; this result is tempered however by
the wide conﬁdence intervals in the seronegative group. Variations
in VPDI and NNV also occurred by individual country in Latin Amer-
ica (Table 2). Mexico for example had a lower VPDI and higher NNV
than Brazil, due to a lower baseline control group incidence com-
bined with a lower vaccine efﬁcacy; the latter in turn may relate to a
lower baseline dengue seropositivity status in Mexico and different
circulating serotypes.
Compared to studies of pneumococcal, Hib, and rotavirus
vaccines in Latin America, dengue vaccine efﬁcacy was similar
ate (NNV) for dengue vaccine compared to other vaccines evaluated and introduced
0 vaccinated persons per year except where otherwise noted.
Vaccine efﬁcacy (95% CI) VPDI NNV
es 65% (59, 70) 1707 28
d cases 80% (65, 89) 239 201
pitalized 96% (69, 100) 73 661
85% (70, 94) 870 200
n 42% (29, 53) 1790 97
alization 40% (28, 50) 2080 84
cal disease 100% (77, 100) 152 1779
eumonia 22% (8, 34) 600 448
f 10% (2, 18) 800 306
9% (4, 14) 1800 135
onsolidation,
levated
26% (7, 44) 250 Not available
immunization to age 1 year.
tion to average of almost 3 years. VPDI reported as cases per 100,000 person-years
ted as PYO.
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Table  4
Comparison of vaccine preventable disease incidence (VPDI) and number needed to vaccinate (NNV) for dengue vaccine compared to other vaccines evaluated and introduced
into  national immunization programs in the Asian-Paciﬁc region. VPDI reported as cases per 100,000 vaccinated persons per year except where otherwise noted.
Etiology Outcome Vaccine efﬁcacy (95% CI) VPDI NNV
Dengue [5] a All virologically conﬁrmed clinical cases 68% (58, 76) 2639 18
All  virologically conﬁrmed hospitalized cases 82% (61, 92) 638 75
All  virologically conﬁrmed severe hospitalized cases 91% (58, 99) 290 166
Rotavirus [14]b Severe rotavirus gastroenteritis (Vesikari score 11+) 48% (22, 66) 3000 29
All  cause severe gastroenteritis 27% (2, 46) 3000 38
Haemophilus
inﬂuenzae type
b (Hib) [13] c
Hib meningitis hospitalization 86% 16 Not available
All  cause meningitis hospitalization 22% 158 Not available
All  cause severe pneumonia 5% 264 Not available
All  cause clinical pneumonia 4% 1561 Not available
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[a Data calculated for persons 9–16 years of age and 2 year follow-up period.
b Data from Bangladesh and Vietnam, for children followed from infant immuniza
c Data from Indonesia for children followed infant immunization to age 2 years. V
gainst etiologically conﬁrmed disease (Table 3). Unlike the dengue
accine trial, trials of the other three vaccines also presented
ata on VE against clinical syndromes including pneumonia out-
omes for pneumococcus and Hib and all cause gastroenteritis for
otavirus. As expected, VE was lower against these clinical syn-
romes reﬂecting that other etiologies were involved. However,
PDI was relatively high indicating that even with relatively low
fﬁcacy, vaccines can have high impact when background disease
ates are high. VPDI for conﬁrmed dengue hospitalization was sim-
lar to that for pneumococcal conjugate vaccine against vaccine
erotype invasive pneumococcal disease and Hib vaccine against
ll cause pneumonia but was lower than that for rotavirus vaccine
gainst all cause severe gastroenteritis and pneumococcal conju-
ate vaccine against all cause pneumonia.
Compared to studies of Hib and rotavirus vaccines in Asia,
engue vaccine efﬁcacy again was similar against etiologically con-
rmed disease (Table 4). VPDI for conﬁrmed dengue hospitalization
as higher than that for Hib vaccine against Hib meningitis or all
ause severe pneumonia while lower than that for rotavirus vaccine
gainst severe rotavirus gastroenteritis.
. Discussion
Policymakers consistently state that national disease burden is
he most important factor in setting priorities for vaccines to be
ntroduced into public sector immunization programs [15]. Despite
his, results from vaccine clinical trials focus on the regulatory con-
erns of vaccine efﬁcacy and safety among individual vaccinated
ubjects and rarely present data in a way that allows assessment of
he expected burden reduction, and thus public health importance,
hat vaccines can achieve. In the absence of this information, policy-
akers and public health advisory groups in affected countries may
ave difﬁculty making rational recommendations and decisions on
hether and how to introduce new vaccines.
Here we present an analysis of data from dengue vaccine clin-
cal trials to illustrate the utility of VPDI, a measure recently
escribed in detail [7,12]. This outcome provides a measure of a
accine’s public health impact by deﬁning how many outcomes
an be prevented over a certain time period by delivering a deﬁned
uantity of vaccine. The related measure of NNV not only pro-
ides a measure of immediate relevance to policy-makers, but also
ncorporates the concept of cases potentially prevented over mul-
iple years following primary immunization. Both measures will
ary with underlying disease epidemiology, such as baseline bur-
en, seasonality, age distribution and where relevant serotype or
erogroup distribution. Less well appreciated is that VE also is
ot an invariant quality and can vary by measured outcome (e.g.,
ower dengue VE against non-severe than hospitalized disease) and
eography (e.g., lower rotavirus VE in Malawi than South Africa
16]). age 2 years, VPDI reported as cases per 100,000 person-years of observation (PYO).
eported as PYO.
Our analysis found that the CYD-TDV dengue vaccine had favor-
able VPDI and NNV when compared to existing vaccines used in
Latin America and Asia. For example, in Asia, the CYD-TDV dengue
vaccine had a VPDI for severe hospitalized disease approximately
equal to the VPDI for severe Hib pneumonia. In Latin America, while
severe disease VPDI was relatively low, the VPDI for all hospitalized
dengue was approximately equal to the sum of invasive Hib disease
and severe pneumonia.
Moreover, dengue vaccine had a high VPDI against less severe
disease, which may  have substantial implications for health service
utilization. Despite the lower VE against serotype 2, the relatively
higher incidence of this serotype led to a VPDI within the range of
other serotypes with the notable exceptions of serotypes 1 and 4
in the Asian-Paciﬁc region. Lastly, we  found variation by baseline
seropositivity (among the subgroup that had seroprevalence deter-
mined) but not co-linear with VE. For example, in Asia the VPDI was
higher and the NNV lower among those who were seronegative at
baseline despite a substantially lower VE among this group.
This occurred despite available data being limited to etio-
logically conﬁrmed disease for dengue while comparisons were
made to VDPIs based on syndromic disease. VPDI for dengue was
calculated for etiologically conﬁrmed disease while comparison
conditions were calculated in part against syndromic disease. VPDI
calculated for etiologically conﬁrmed disease likely will be lower
than that for syndromic disease because diagnostic tests have
imperfect sensitivity, not all persons with suspected dengue are
tested, and system errors (e.g., delays between specimen collection
and processing) can lead to false negatives. In Finland, for example,
rotavirus vaccine prevented over twice as many cases of all cause
as rotavirus-conﬁrmed inpatient acute gastroenteritis [17]. Addi-
tionally, the individually randomized nature of the dengue trials
prevented inclusion of indirect effects. Consequently, the values
presented here should be considered a lower bound on the dengue
vaccine’s ability to reduce burden.
VPDI is an important measure but other issues affect a vac-
cine’s public health importance [18]. For example, dengue vaccine
in principle can prevent disease across all age groups while the
beneﬁts of rotavirus and largely Hib vaccine are limited to early
childhood. Furthermore, a dengue vaccine can prevent the poten-
tially large effects of dengue outbreaks on health, health systems,
and the economy [19]. On the other hand, dengue rarely causes sig-
niﬁcant long-term sequelae and has a relatively low mortality rate
[2], similar to rotavirus but distinct from the devastating sequelae
and high mortality often caused by invasive pneumococcal and Hib
disease.
Our study was not set out to address safety issues and is limited
to the ﬁrst 2 years of the trial. During the third year of the CYD-
TDV trial, a higher number of hospitalizations were observed in the
vaccinated group compared to the unvaccinated group for those
individuals of 2 to 5 years of age. The reversed risk:beneﬁt ratio is
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f concern and further long-term follow-up of the phase 3 study
articipants is ongoing. No such reversed risk:beneﬁt ratio was
bserved in subjects aged 9–16 years – the age group for which
icensure has been sought [20]. Because of the ongoing concern
bout potential antibody-dependent enhancement at the time of
aning efﬁcacy, the World Health Organization recommends that
urveillance for possible immune enhanced disease should be con-
inued for 5 years after vaccination [21]. Waning efﬁcacy after two
ears may  occur [22]. However, such waning will not affect the
PDI and NNV estimates presented here as these estimates derived
irectly from the clinical trial results during the two-year reporting
eriod. Waning immunity may  diminish VPDI and NNV beyond the
wo-year period. Studies are currently being introduced by Sanoﬁ
asteur to evaluate the need and timing of vaccine boosters.
Our data on VPDI and NNV can aid in cost effectiveness stud-
es once the price of the vaccine is known. Other issues that will
eed to be addressed include issues such as immune duration,
ariable distribution of disease burden within countries, and pro-
rammatic issues such as vaccine schedule requirements. Some
f these remaining questions for CYD-TDV can be addressed rea-
onably with existing data from the Phase 3 trials or future data.
or example, if the existing trials collected vaccine impact on
yndromic disease, this should be analyzed and reported. Post-
icensure surveillance also will help to further quantify vaccine
ffectiveness at the population level, conﬁrm VPDI estimates
eported here, assess long-term safety, aid in determining the
est timing for booster doses, and measure the indirect effect of
he vaccine [18]. More generally, we suggest that VPDI and NNV
hould be presented alongside VE in primary trial reports and
ncluded in trial designs and analytic plans. For example, vaccines
redicted to have substantial indirect effects could have a commu-
ity (or cluster) rather than individually randomized design. Trials
hould assess both etiologically conﬁrmed and clinically deﬁned
utcomes.
In summary, our analysis documents a reasonably high VPDI
nd low NNV, varying from country to country, and dependent
n serotype distribution and baseline seropositivity. These ﬁndings
ill help public health advisory groups and policy-makers decide
here and how to introduce the ﬁrst dengue vaccine.
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